Answers are grounded in this paper and cite their sources.
Vascular inflammation, marked by endothelial dysfunction and overexpression of proinflammatory cytokines such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), is a key contributor to atherosclerosis. Oleuropein (Ole), a phenolic compound with proven anti-inflammatory properties, suffers from poor aqueous stability and limited oral bioavailability, constraining its clinical application. To overcome these limitations, we developed and optimized chitosan (CS)-coated liposomes for oral delivery of Ole. Using a Box-Behnken design, the optimized formulation exhibited a particle size of 168.73 ± 3.86 nm, a polydispersity index (PDI) of 0.17 ± 0.01, a moderate negative zeta potential (−22.50 ± 2.39 mV), an encapsulation efficiency of 87.17 ± 0.27%, and a loading capacity of 12.22 ± 0.25%. The CS-coated formulation retained acceptable colloidal stability under refrigerated storage, enabled pH-responsive sustained release governed by Fickian diffusion, and enhanced endothelial nanocarrier uptake in EA.hy926 cells. The formulation was well tolerated in vitro, with cell viability exceeding 90% across a 500–4000 ng/mL concentration range. In a TNF-α-induced murine model of acute vascular inflammation, daily oral administration of CS-Ole-Lip (20 mg/kg) significantly suppressed serum IL-6 by 6.90-fold (p < 0.05) and MCP-1 by 2.45-fold relative to TNF-α controls (p < 0.0001), with numerically greater suppression than that observed with free Ole and uncoated Ole-Lip at the same dose. CS-Ole-Lip at 2 mg/kg, one-tenth of the 20 mg/kg dose evaluated in this study, produced substantial serum cytokine suppression, suggesting a potential dose-sparing effect. No treatment-associated elevations in the evaluated serum markers of hepatic or renal function or overt histological abnormalities in the examined organs were observed. These findings support CS-Ole-Lip as a stable oral nanocarrier with enhanced anti-inflammatory pharmacodynamic activity. The mechanistic basis for the dose-sparing effect requires direct pharmacokinetic and molecular validation.
No takes yet. Share an insight, caveat, or question.
Pajimna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: